priors.science/reviews/hypertension-management

Hypertension Management

The current evidence on 20 claims, ordered from most established to most contested. Each score is the panel’s evidence certainty — how firmly the literature supports the claim as stated.

20claims tracked
185primary papers reviewed
6 Jul 2026latest evidence review
Weeklyre-scored against new papers
9 Established · 11 Likely · 0 Uncertain · 0 Doubtful  |  four-reviewer panel · PICO Framework
SignalClaimStandingEvidence certaintyCorpus
StableSGLT2 inhibitors reduce chronic kidney disease progressionRaas CKDEstablished93%10
StableDual renin-angiotensin-aldosterone system blockade increases renal riskDrug ClassesEstablished91%8
StableFinerenone reduces cardiovascular and renal eventsMra FinerenoneEstablished91%10
StableSpironolactone superior fourth-line agent in resistant hypertensionResistant HTNEstablished91%10
StableIntensive systolic blood pressure below 120 reduces major cardiovascular eventsBP TargetsEstablished90%15
StableSodium restriction lowers blood pressureLifestyleEstablished90%10
StableCalcium channel blocker versus angiotensin-converting enzyme inhibitor cardiovascular outcomesDrug ClassesEstablished89%8
StableIntensive blood pressure control reduces stroke in type 2 diabetesBP TargetsEstablished88%10
StableDASH diet plus sodium restriction lowers blood pressureLifestyleEstablished86%8
StableFinerenone reduces heart failure hospitalizationsMra FinerenoneLikely81%10
StableAmbulatory blood pressure monitoring superior to office blood pressure for cardiovascular riskSpecial PopulationsLikely81%8
StablePrimary aldosteronism is under-diagnosedPrimary AldosteronismLikely79%8
StableSGLT2 inhibitors lower nocturnal blood pressureSglt2 HTNLikely79%9
StableBeta-blocker inferior as first-line agentDrug ClassesLikely78%8
StableAldosterone-to-renin ratio screening for primary aldosteronismPrimary AldosteronismLikely77%8
StableRenal denervation reduces systolic blood pressureResistant HTNLikely76%10
StableWhite-coat hypertension increases cardiovascular riskSpecial PopulationsLikely75%10
StableLow diastolic blood pressure J-curve risk in coronary artery diseaseBP TargetsLikely73%9
StableStopping renin-angiotensin-aldosterone system inhibitor has no benefit in chronic kidney diseaseRaas CKDLikely73%8
StableIntensive blood pressure treatment in frail elderlySpecial PopulationsLikely73%8
Standing — what the evidence certainty means
Established≥ 85%Strong, consistent evidence. Unlikely to change.
Likely65–84%Well supported, with some gaps or indirect evidence.
Uncertain40–64%Mixed or limited evidence. Genuinely open.
Doubtful15–39%Little support; the weight of evidence leans against it.
Refuted< 15%The evidence contradicts it — confidently false as stated.
Recent signal
strengthenedNew evidence raised the certainty since the last review.
weakenedNew evidence lowered the certainty since the last review.
newA claim added to the review recently.
StableNo recent change to the standing.
Standing, evidence certainty and corpus are always shown. The study behind each move, why it moved, and the sceptic’s challenge are delivered to subscribers.
Update your priors.Track this topic